You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDuloxetine
Accession NumberDB00476  (APRD00060)
TypeSmall Molecule
GroupsApproved
DescriptionDuloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company. Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia. Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake.
Structure
Thumb
Synonyms
(3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine
(S)-duloxetine
External Identifiers
  • LY 248686
  • LY-248686
  • LY248686
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Duloxetinecapsule (delayed release)60 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Act Duloxetinecapsule (delayed release)30 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
AriclaimGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
AriclaimGastro-resistant capsule, hard30 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
AriclaimGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
AriclaimGastro-resistant capsule, hard30 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
AriclaimGastro-resistant capsule, hard30 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
Auro-duloxetinecapsule (delayed release)60 mgoralAuro Pharma Inc2016-05-02Not applicableCanada
Auro-duloxetinecapsule (delayed release)30 mgoralAuro Pharma Inc2016-05-02Not applicableCanada
Cymbaltacapsule, delayed release60 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-01-15Not applicableUs
Cymbaltacapsule, delayed release60 mg/1oralCardinal Health2004-08-24Not applicableUs
CymbaltaGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
Cymbaltacapsule, delayed release20 mg/1oralEli Lilly and Company2004-08-24Not applicableUs
Cymbaltacapsule, delayed release60 mg/1oralUnit Dose Services2010-01-15Not applicableUs
Cymbaltacapsule, delayed release30 mg/1oralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-07-14Not applicableUs
Cymbaltacapsule, delayed release60 mg/1oralSt Marys Medical Park Pharmacy2010-12-31Not applicableUs
Cymbaltacapsule, delayed release60 mg/1oralRebel Distributors Corp.2004-08-24Not applicableUs
Cymbaltacapsule, delayed release30 mg/1oralPhysicians Total Care, Inc.2008-11-21Not applicableUs
Cymbaltacapsule, delayed release20 mg/1oralCarilion Materials Management2004-08-24Not applicableUs
CymbaltaGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
Cymbaltacapsule, delayed release30 mg/1oralSTAT Rx USA LLC2004-08-24Not applicableUs
Cymbaltacapsule, delayed release60 mg/1oralPd Rx Pharmaceuticals, Inc.2010-01-15Not applicableUs
Cymbaltacapsule (delayed release)30 mgoralEli Lilly Canada Inc2008-01-18Not applicableCanada
CymbaltaGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
Cymbaltacapsule, delayed release30 mg/1oralEli Lilly and Company2004-08-24Not applicableUs
Cymbaltacapsule, delayed release60 mg/1oralH.J. Harkins Company, Inc.2010-01-15Not applicableUs
Cymbaltacapsule, delayed release60 mg/1oralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-07-14Not applicableUs
Cymbaltacapsule, delayed release30 mg/1oralSt Marys Medical Park Pharmacy2010-12-31Not applicableUs
Cymbaltacapsule, delayed release20 mg/1oralRebel Distributors Corp2004-08-24Not applicableUs
Cymbaltacapsule, delayed release30 mg/1oralCardinal Health2004-08-24Not applicableUs
CymbaltaGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
Cymbaltacapsule (delayed release)60 mgoralEli Lilly Canada Inc2008-01-18Not applicableCanada
Cymbaltacapsule, delayed release30 mg/1oralAphena Pharma Solutions Tennessee, Llc2004-08-24Not applicableUs
Cymbaltacapsule, delayed release30 mg/1oralPd Rx Pharmaceuticals, Inc.2004-08-24Not applicableUs
Cymbaltacapsule, delayed release30 mg/1oralCarilion Materials Management2004-08-24Not applicableUs
CymbaltaGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
Cymbaltacapsule, delayed release60 mg/1oralEli Lilly and Company2010-01-15Not applicableUs
Cymbaltacapsule, delayed release60 mg/1oralPhysicians Total Care, Inc.2009-11-23Not applicableUs
Cymbaltacapsule, delayed release20 mg/1oralUnit Dose Services2004-08-24Not applicableUs
Cymbaltacapsule, delayed release60 mg/1oralbryant ranch prepack2010-01-15Not applicableUs
CymbaltaGastro-resistant capsule, hard30 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
Cymbaltacapsule, delayed release30 mg/1oralREMEDYREPACK INC.2013-04-102016-04-05Us
Cymbaltacapsule, delayed release20 mg/1oralCardinal Health2004-08-24Not applicableUs
CymbaltaGastro-resistant capsule, hard30 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
Cymbaltacapsule, delayed release60 mg/1oralClinical Solutions Wholesale2010-01-15Not applicableUs
Cymbaltacapsule, delayed release60 mg/1oralREMEDYREPACK INC.2010-12-23Not applicableUs
Cymbaltacapsule, delayed release30 mg/1oralRebel Distributors Corp.2004-08-24Not applicableUs
Cymbaltacapsule, delayed release20 mg/1oralPhysicians Total Care, Inc.2008-04-28Not applicableUs
CymbaltaGastro-resistant capsule, hard30 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
Cymbaltacapsule, delayed release30 mg/1oralUnit Dose Services2004-08-24Not applicableUs
Cymbaltacapsule, delayed release30 mg/1oralbryant ranch prepack2004-08-24Not applicableUs
CymbaltaGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
Dom-duloxetinecapsule (delayed release)30 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-duloxetinecapsule (delayed release)60 mgoralDominion PharmacalNot applicableNot applicableCanada
Duloxetinecapsule (delayed release)60 mgoralSivem Pharmaceuticals Ulc2016-05-05Not applicableCanada
Duloxetinecapsule, delayed release20 mg/1oralPrasco Laboratories2014-01-24Not applicableUs
Duloxetinecapsule (delayed release)30 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Duloxetinecapsule (delayed release)30 mgoralPro Doc Limitee2016-05-03Not applicableCanada
Duloxetinecapsule, delayed release30 mg/1oralPrasco Laboratories2014-01-24Not applicableUs
Duloxetinecapsule (delayed release)60 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Duloxetinecapsule, delayed release60 mg/1oralPrasco Laboratories2014-01-242015-11-30Us
Duloxetinecapsule (delayed release)60 mgoralPro Doc Limitee2016-05-03Not applicableCanada
Duloxetinecapsule (delayed release)30 mgoralSivem Pharmaceuticals Ulc2016-05-05Not applicableCanada
Duloxetinecapsule, delayed release60 mg/1oralCarilion Materials Management2014-01-24Not applicableUs
Duloxetine Drcapsule (delayed release)30 mgoralTeva Canada Limited2016-05-02Not applicableCanada
Duloxetine Drcapsule (delayed release)60 mgoralTeva Canada Limited2016-05-02Not applicableCanada
Duloxetine LillyGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyGastro-resistant capsule, hard30 mgOral useEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyGastro-resistant capsule, hard30 mgOral useEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyGastro-resistant capsule, hard30 mgOral useEli Lilly Nederland B.V.2014-12-08Not applicableEu
Ipg-duloxetinecapsule (delayed release)60 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-duloxetinecapsule (delayed release)30 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-duloxetinecapsule (delayed release)30 mgoralJamp Pharma Corporation2016-05-03Not applicableCanada
Jamp-duloxetinecapsule (delayed release)60 mgoralJamp Pharma Corporation2016-05-03Not applicableCanada
Mar-duloxetinecapsule (delayed release)30 mgoralMarcan Pharmaceuticals Inc2016-05-10Not applicableCanada
Mar-duloxetinecapsule (delayed release)60 mgoralMarcan Pharmaceuticals Inc2016-05-10Not applicableCanada
Mint-duloxetinecapsule (delayed release)30 mgoralMint Pharmaceuticals Inc2016-05-02Not applicableCanada
Mint-duloxetinecapsule (delayed release)60 mgoralMint Pharmaceuticals Inc2016-05-02Not applicableCanada
Mylan-duloxetinecapsule (delayed release)60 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-duloxetinecapsule (delayed release)30 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
PMS-duloxetinecapsule (delayed release)30 mgoralPharmascience Inc2016-05-02Not applicableCanada
PMS-duloxetinecapsule (delayed release)60 mgoralPharmascience Inc2016-05-02Not applicableCanada
Ran-duloxetinecapsule (delayed release)60 mgoralRanbaxy Pharmaceuticals Canada Inc.2016-05-02Not applicableCanada
Ran-duloxetinecapsule (delayed release)30 mgoralRanbaxy Pharmaceuticals Canada Inc.2016-05-02Not applicableCanada
Riva-duloxetinecapsule (delayed release)30 mgoralLaboratoire Riva Inc2016-05-02Not applicableCanada
Riva-duloxetinecapsule (delayed release)60 mgoralLaboratoire Riva Inc2016-05-12Not applicableCanada
Sandoz Duloxetinecapsule (delayed release)30 mgoralSandoz Canada Incorporated2016-05-02Not applicableCanada
Sandoz Duloxetinecapsule (delayed release)60 mgoralSandoz Canada Incorporated2016-05-02Not applicableCanada
Taro-duloxetinecapsule (delayed release)30 mgoralTaro Pharmaceuticals IncNot applicableNot applicableCanada
Taro-duloxetinecapsule (delayed release)60 mgoralTaro Pharmaceuticals IncNot applicableNot applicableCanada
Teva-duloxetine Drcapsule (delayed release)30 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Teva-duloxetine Drcapsule (delayed release)60 mgoralTeva Canada LimitedNot applicableNot applicableCanada
XeristarGastro-resistant capsule, hard30 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarGastro-resistant capsule, hard30 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarGastro-resistant capsule, hard60 mgOral useEli Lilly Nederland B.V.2004-12-17Not applicableEu
YentreveGastro-resistant capsule, hard20 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveGastro-resistant capsule, hard20 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveGastro-resistant capsule, hard40 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveGastro-resistant capsule, hard40 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveGastro-resistant capsule, hard40 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveGastro-resistant capsule, hard40 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveGastro-resistant capsule, hard20 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveGastro-resistant capsule, hard40 mgOral useEli Lilly Nederland B.V.2004-08-11Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-duloxetinecapsule (delayed release)30 mgoralApotex Inc2016-05-03Not applicableCanada
Apo-duloxetinecapsule (delayed release)60 mgoralApotex Inc2016-05-03Not applicableCanada
Duloxetinecapsule, delayed release20 mg/1oralTeva Pharmaceuticals Usa, Inc.2013-12-11Not applicableUs
Duloxetinecapsule, delayed release pellets30 mg/1oralMedsource Pharmaceuticals2014-06-18Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralREMEDYREPACK INC.2014-04-24Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralTYA Pharmaceuticals2013-12-11Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralAscend Laboratories, LLC2012-05-01Not applicableUs
Duloxetinecapsule, delayed release pellets30 mg/1oralPreferred Pharmaceuticals, Inc.2014-11-18Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralLupin Pharmaceuticals, Inc.2013-12-11Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralCipla USA Inc.2015-12-05Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralKAISER FOUNDATION HOSPITALS2014-01-20Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralTrigen Laboratories, LLC2014-08-19Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralCardinal Health2013-12-11Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralAurobindo Pharma Limited2013-12-11Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralCardinal Health2013-12-23Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralCadila Healthcare Limited2014-05-27Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralAmerican Health Packaging2013-12-23Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralAvera Mc Kennan Hospital2015-03-09Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralAv Kare, Inc.2014-07-08Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralCitron Pharma LLC2013-12-11Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralbryant ranch prepack2013-12-11Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralPrasco Laboratories2013-12-11Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-05-27Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralProficient Rx LP2013-12-11Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralBlue Point Laboratories2014-03-14Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralTeva Pharmaceuticals Usa, Inc.2013-12-11Not applicableUs
Duloxetinecapsule, delayed release pellets60 mg/1oralMedsource Pharmaceuticals2014-06-18Not applicableUs
Duloxetinecapsule, delayed release pellets20 mg/1oralDr. Reddy's Laboratories Limited2014-06-18Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralCadila Healthcare Limited2014-02-15Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralAurobindo Pharma Limited2013-12-11Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralLupin Pharmaceuticals, Inc.2013-12-11Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralCipla USA Inc.2015-12-05Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralActavis Pharma, Inc.2013-12-17Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralTrigen Laboratories, LLC2014-08-19Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralCardinal Health2013-12-11Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralSun Pharma Global FZE2013-12-11Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralCardinal Health2013-12-23Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralCadila Healthcare Limited2014-05-27Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralAmerican Health Packaging2013-12-23Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralAv Kare, Inc.2014-07-08Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralREMEDYREPACK INC.2014-01-302016-04-05Us
Duloxetinecapsule, delayed release20 mg/1oralAscend Laboratories, LLC2012-05-01Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-05-27Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralCadila Healthcare Limited2014-02-15Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralBlue Point Laboratories2014-03-14Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralTeva Pharmaceuticals Usa, Inc.2013-12-11Not applicableUs
Duloxetinecapsule, delayed release pellets30 mg/1oralDr. Reddy's Laboratories Limited2014-06-18Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralCitron Pharma LLC2013-12-11Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralPrasco Laboratories2013-12-11Not applicableUs
Duloxetinecapsule, delayed release40 mg/1oralLupin Pharmaceuticals, Inc.2015-05-25Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralAvera Mc Kennan Hospital2015-03-02Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralActavis Pharma, Inc.2013-12-17Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralTrigen Laboratories, LLC2014-08-19Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralSun Pharma Global FZE2013-12-11Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralCadila Healthcare Limited2014-05-27Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralAmerican Health Packaging2013-12-23Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralA S Medication Solutions2013-12-11Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralAv Kare, Inc.2014-07-08Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralREMEDYREPACK INC.2014-01-302016-04-05Us
Duloxetinecapsule, delayed release30 mg/1oralAscend Laboratories, LLC2012-05-01Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralPreferred Pharmaceuticals, Inc.2014-11-25Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralProficient Rx LP2013-12-11Not applicableUs
Duloxetinecapsule, delayed release pellets60 mg/1oralDr. Reddy's Laboratories Limited2014-06-18Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralCadila Healthcare Limited2014-02-15Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralBlue Point Laboratories2014-03-14Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralActavis Pharma, Inc.2013-12-17Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralCitron Pharma LLC2013-12-11Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralbryant ranch prepack2013-12-11Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralPrasco Laboratories2013-12-11Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-05-27Not applicableUs
Duloxetinecapsule, delayed release30 mg/1oralREMEDYREPACK INC.2016-01-26Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralSun Pharma Global FZE2013-12-11Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralCardinal Health2013-12-11Not applicableUs
Duloxetinecapsule, delayed release60 mg/1oralDIRECT RX2014-01-01Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralAurobindo Pharma Limited2013-12-11Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralLupin Pharmaceuticals, Inc.2013-12-11Not applicableUs
Duloxetinecapsule, delayed release20 mg/1oralCipla USA Inc.2015-12-05Not applicableUs
Duloxetine Delayed-releasecapsule, delayed release pellets60 mg/1oralGolden State Medical Supply, Inc.2014-06-11Not applicableUs
Duloxetine Delayed-releasecapsule, delayed release pellets30 mg/1oralBlenheim Pharmacal, Inc.2016-04-01Not applicableUs
Duloxetine Delayed-releasecapsule, delayed release pellets60 mg/1oralBreckenridge Pharmaceutical, Inc.2014-06-11Not applicableUs
Duloxetine Delayed-releasecapsule, delayed release pellets30 mg/1oralPreferred Pharmaceuticals, Inc.2015-03-23Not applicableUs
Duloxetine Delayed-releasecapsule, delayed release pellets60 mg/1oralA S Medication Solutions2014-06-11Not applicableUs
Duloxetine Delayed-releasecapsule, delayed release pellets20 mg/1oralGolden State Medical Supply, Inc.2014-06-11Not applicableUs
Duloxetine Delayed-releasecapsule, delayed release pellets30 mg/1oralTYA Pharmaceuticals2014-06-11Not applicableUs
Duloxetine Delayed-releasecapsule, delayed release pellets20 mg/1oralBreckenridge Pharmaceutical, Inc.2014-06-11Not applicableUs
Duloxetine Delayed-releasecapsule, delayed release pellets30 mg/1oralGolden State Medical Supply, Inc.2014-06-11Not applicableUs
Duloxetine Delayed-releasecapsule, delayed release pellets60 mg/1oralBlenheim Pharmacal, Inc.2016-04-01Not applicableUs
Duloxetine Delayed-releasecapsule, delayed release pellets30 mg/1oralBreckenridge Pharmaceutical, Inc.2014-06-11Not applicableUs
Duloxetine Delayed-release Delayed-releasecapsule, delayed release pellets30 mg/1oralREMEDYREPACK INC.2016-03-14Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release30 mg/1oralMajor Pharmaceuticals2013-12-11Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release30 mg/1oralUnit Dose Services2013-12-11Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release30 mg/1oralProficient Rx LP2014-06-13Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release60 mg/1oralMajor Pharmaceuticals2014-06-13Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release60 mg/1oralApotex Corp.2014-06-13Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-12-11Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release60 mg/1oralMajor Pharmaceuticals2013-12-11Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release20 mg/1oralApotex Corp.2014-06-13Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release60 mg/1oralProficient Rx LP2014-06-13Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release60 mg/1oralUnit Dose Services2013-12-11Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release20 mg/1oralTorrent Pharmaceuticals Limited2013-12-11Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release pellets60 mg/1oralDIRECT RX2014-01-01Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release60 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-12-11Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release30 mg/1oralApotex Corp.2014-06-13Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release30 mg/1oralPreferred Pharmaceuticals, Inc.2014-08-20Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release20 mg/1oralMajor Pharmaceuticals2014-06-13Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release60 mg/1oralProficient Rx LP2013-12-11Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release30 mg/1oralTorrent Pharmaceuticals Limited2013-12-11Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release30 mg/1oralCardinal Health2013-12-11Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release pellets30 mg/1oralDIRECT RX2014-01-01Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release20 mg/1oralMajor Pharmaceuticals2013-12-11Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release30 mg/1oralTYA Pharmaceuticals2013-12-11Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release60 mg/1oralApotex Corp.2014-06-13Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release20 mg/1oralPreferred Pharmaceuticals, Inc.2014-08-20Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release30 mg/1oralMajor Pharmaceuticals2014-06-13Not applicableUs
Duloxetine Hydrochloridecapsule, delayed release60 mg/1oralTorrent Pharmaceuticals Limited2013-12-11Not applicableUs
Duloxetine Hydrochloride 20 mgcapsule, delayed release20 mg/1oralAlembic Pharmaceuticals Limited2014-06-09Not applicableUs
Duloxetine Hydrochloride 30 mgcapsule, delayed release30 mg/1oralAlembic Pharmaceuticals Limited2014-06-09Not applicableUs
Duloxetine Hydrochloride 60 mgcapsule, delayed release60 mg/1oralAlembic Pharmaceuticals Limited2014-06-09Not applicableUs
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard30 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanGastro-resistant capsule, hard60 mgOral useGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine ZentivaGastro-resistant capsule, hard30 mgOral useZentiva, K.S.2015-08-20Not applicableEu
Duloxetine ZentivaGastro-resistant capsule, hard60 mgOral useZentiva, K.S.2015-08-20Not applicableEu
Duloxetine ZentivaGastro-resistant capsule, hard60 mgOral useZentiva, K.S.2015-08-20Not applicableEu
Duloxetine ZentivaGastro-resistant capsule, hard30 mgOral useZentiva, K.S.2015-08-20Not applicableEu
Duloxetine ZentivaGastro-resistant capsule, hard60 mgOral useZentiva, K.S.2015-08-20Not applicableEu
Duloxetine ZentivaGastro-resistant capsule, hard30 mgOral useZentiva, K.S.2015-08-20Not applicableEu
Duloxetine ZentivaGastro-resistant capsule, hard60 mgOral useZentiva, K.S.2015-08-20Not applicableEu
Irenkacapsule, delayed release40 mg/1oralLupin Pharma2015-06-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AriclaimNot Available
DulaneNot Available
DuzelaNot Available
XeristarNot Available
YentreveNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Duloxetine hydrochloride
136434-34-9
Thumb
  • InChI Key: BFFSMCNJSOPUAY-LMOVPXPDSA-N
  • Monoisotopic Mass: 333.0954131
  • Average Mass: 333.87
DBSALT000378
Categories
UNIIO5TNM5N07U
CAS number116539-59-4
WeightAverage: 297.415
Monoisotopic: 297.118734925
Chemical FormulaC18H19NOS
InChI KeyInChIKey=ZEUITGRIYCTCEM-KRWDZBQOSA-N
InChI
InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
IUPAC Name
methyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine
SMILES
CNCC[[email protected]](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassNaphthalenes
Sub ClassNot Available
Direct ParentNaphthalenes
Alternative Parents
Substituents
  • Naphthalene
  • Aralkylamine
  • Alkyl aryl ether
  • Heteroaromatic compound
  • Thiophene
  • Organoheterocyclic compound
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women.
PharmacodynamicsDuloxetine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) and primarily targets major depressive disorders (MDD) and stress urinary incontinence (SUI). Duloxetine is also used to treat pain and tingling caused by diabetic neuropathy (damage to nerves that can develop in people who have diabetes). Known also as LY248686, it is a potent dual inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake, possessing comparable affinities in binding to NE and 5-HT transport sites. Interestingly, its behavior contrasts to most other dual-reuptake inhibitors. Furthermore, duloxentine lacks affinity for monoamine receptors within the central nervous system.
Mechanism of actionDuloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors. The antidepressant and pain inhibitory actions of duloxetine are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. The mechanism of action of duloxetine in SUI has not been determined, but is thought to be associated with the potentiation of serotonin and norepinephrine activity in the spinal cord, which increases urethral closure forces and thereby reduces involuntary urine loss.
Related Articles
AbsorptionOrally administered duloxetine hydrochloride is well absorbed.
Volume of distribution
  • 1640 L
Protein bindingProtein binding is greater than 90%.
Metabolism

The major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation. Both CYP2D6 and CYP1A2 catalyze the oxidation of the naphthyl ring in vitro. Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. The major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine.

SubstrateEnzymesProduct
Duloxetine
Not Available
4-hydroxy duloxetine glucuronideDetails
Duloxetine
Not Available
5-hydroxy, 6-methoxy duloxetine sulfateDetails
Route of eliminationMany additional metabolites have been identified in urine, some representing only minor pathways of elimination. Most (about 70%) of the duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is excreted in the feces.
Half life12 hours (range 8-17 hours)
ClearanceNot Available
ToxicityOral, rat LD50: 491 mg/kg for males and 279 mg/kg for females. Symptoms of overdose include tremors, convulsions, reduced activity, slow pupillary response, intermittent tremors, and rigidity.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9804
Caco-2 permeable+0.6358
P-glycoprotein substrateSubstrate0.7078
P-glycoprotein inhibitor IInhibitor0.5987
P-glycoprotein inhibitor IINon-inhibitor0.5519
Renal organic cation transporterInhibitor0.6525
CYP450 2C9 substrateNon-substrate0.5964
CYP450 2D6 substrateSubstrate0.6482
CYP450 3A4 substrateSubstrate0.5799
CYP450 1A2 substrateInhibitor0.839
CYP450 2C9 inhibitorNon-inhibitor0.7721
CYP450 2D6 inhibitorInhibitor0.6977
CYP450 2C19 inhibitorNon-inhibitor0.572
CYP450 3A4 inhibitorInhibitor0.5108
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6689
Ames testNon AMES toxic0.5422
CarcinogenicityNon-carcinogens0.9293
BiodegradationNot ready biodegradable0.935
Rat acute toxicity2.5700 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5926
hERG inhibition (predictor II)Inhibitor0.6386
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Capsule (delayed release)oral30 mg
Capsule (delayed release)oral60 mg
Capsule, delayed releaseoral20 mg/1
Capsule, delayed releaseoral30 mg/1
Capsule, delayed releaseoral60 mg/1
Capsule, delayed release pelletsoral30 mg/1
Capsule, delayed release pelletsoral60 mg/1
Capsule, delayed release pelletsoral20 mg/1
Gastro-resistant capsule, hardOral use30 mg
Gastro-resistant capsule, hardOral use60 mg
Capsule, delayed releaseoral40 mg/1
Gastro-resistant capsule, hardOral use20 mg
Gastro-resistant capsule, hardOral use40 mg
Prices
Unit descriptionCostUnit
Cymbalta 30 mg Enteric Coated Capsule5.38USD capsule
Cymbalta 60 mg Enteric Coated Capsule5.38USD capsule
Cymbalta 30 mg capsule5.18USD capsule
Cymbalta 60 mg capsule5.18USD capsule
Cymbalta 20 mg Enteric Coated Capsule4.64USD capsule
Cymbalta 20 mg capsule4.62USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2153856 No2005-05-102015-07-13Canada
CA2344057 No2008-11-182019-09-10Canada
US5023269 No1993-06-112013-06-11Us
US6596756 Yes2000-03-102020-03-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00296 mg/mLALOGPS
logP4.72ALOGPS
logP4.2ChemAxon
logS-5ALOGPS
pKa (Strongest Basic)9.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity87.73 m3·mol-1ChemAxon
Polarizability33.15 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Richard A. Berglund, “Intermediate useful for the asymmetric synthesis of duloxetine.” U.S. Patent US5491243, issued June, 1991.

US5491243
General References
  1. Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P: Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001 May;24(5):511-21. [PubMed:11282251 ]
  2. Anttila S, Leinonen E: Duloxetine Eli Lilly. Curr Opin Investig Drugs. 2002 Aug;3(8):1217-21. [PubMed:12211418 ]
  3. Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev. 2002 Winter;8(4):361-76. [PubMed:12481192 ]
  4. van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9. [PubMed:2784100 ]
  5. Jost W, Marsalek P: Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. Clin Auton Res. 2004 Aug;14(4):220-7. [PubMed:15316838 ]
  6. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470 ]
External Links
ATC CodesN06AX21
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (104 KB)
MSDSDownload (76.3 KB)
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Duloxetine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Duloxetine.
AbirateroneThe serum concentration of Duloxetine can be increased when it is combined with Abiraterone.
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Duloxetine.
AcepromazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Duloxetine.
AcetazolamideAcetazolamide may increase the orthostatic hypotensive activities of Duloxetine.
AcetophenazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Acetophenazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Duloxetine.
Acetylsalicylic acidDuloxetine may increase the antiplatelet activities of Acetylsalicylic acid.
AgmatineDuloxetine may decrease the antihypertensive activities of Agmatine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Duloxetine.
AldesleukinAldesleukin may increase the orthostatic hypotensive activities of Duloxetine.
AliskirenAliskiren may increase the orthostatic hypotensive activities of Duloxetine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Duloxetine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Duloxetine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Duloxetine.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Duloxetine.
AmilorideAmiloride may increase the orthostatic hypotensive activities of Duloxetine.
AmineptineDuloxetine may increase the serotonergic activities of Amineptine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Duloxetine.
AmiodaroneThe serum concentration of Duloxetine can be increased when it is combined with Amiodarone.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Duloxetine.
AmisulprideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amisulpride.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Duloxetine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Duloxetine.
AmlodipineAmlodipine may increase the orthostatic hypotensive activities of Duloxetine.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Duloxetine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Duloxetine.
AmperozideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amperozide.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Duloxetine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Duloxetine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Duloxetine.
Amyl NitriteAmyl Nitrite may increase the orthostatic hypotensive activities of Duloxetine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Duloxetine.
ApomorphineDuloxetine may decrease the antihypertensive activities of Apomorphine.
ApraclonidineApraclonidine may increase the orthostatic hypotensive activities of Duloxetine.
AprindineThe metabolism of Aprindine can be decreased when combined with Duloxetine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Duloxetine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Duloxetine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Duloxetine.
ArtemetherThe metabolism of Artemether can be decreased when combined with Duloxetine.
AsenapineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Duloxetine.
AtenololAtenolol may increase the orthostatic hypotensive activities of Duloxetine.
AtomoxetineThe metabolism of Duloxetine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Azaperone.
AzelastineThe metabolism of Azelastine can be decreased when combined with Duloxetine.
Azilsartan medoxomilAzilsartan medoxomil may increase the orthostatic hypotensive activities of Duloxetine.
AzithromycinThe metabolism of Duloxetine can be decreased when combined with Azithromycin.
BenazeprilBenazepril may increase the orthostatic hypotensive activities of Duloxetine.
BendroflumethiazideBendroflumethiazide may increase the orthostatic hypotensive activities of Duloxetine.
BenmoxinBenmoxin may increase the serotonergic activities of Duloxetine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Duloxetine.
BenzphetamineDuloxetine may decrease the antihypertensive activities of Benzphetamine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Duloxetine.
BepridilThe metabolism of Bepridil can be decreased when combined with Duloxetine.
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Duloxetine.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Duloxetine.
BethanidineDuloxetine may decrease the antihypertensive activities of Bethanidine.
BifeprunoxThe risk or severity of adverse effects can be increased when Duloxetine is combined with Bifeprunox.
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Duloxetine.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Duloxetine.
BortezomibThe metabolism of Duloxetine can be decreased when combined with Bortezomib.
BretyliumBretylium may increase the orthostatic hypotensive activities of Duloxetine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Duloxetine.
BrimonidineBrimonidine may increase the orthostatic hypotensive activities of Duloxetine.
BrimonidineDuloxetine may decrease the antihypertensive activities of Brimonidine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Duloxetine.
BromocriptineDuloxetine may decrease the antihypertensive activities of Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Duloxetine.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Duloxetine.
BumetanideBumetanide may increase the orthostatic hypotensive activities of Duloxetine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Duloxetine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Duloxetine.
BupropionThe serum concentration of Duloxetine can be increased when it is combined with Bupropion.
BupropionThe metabolism of Bupropion can be decreased when combined with Duloxetine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Duloxetine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Duloxetine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Duloxetine.
CaffeineThe metabolism of Duloxetine can be decreased when combined with Caffeine.
CanagliflozinCanagliflozin may increase the orthostatic hypotensive activities of Duloxetine.
CandesartanCandesartan may increase the orthostatic hypotensive activities of Duloxetine.
CaptoprilCaptopril may increase the orthostatic hypotensive activities of Duloxetine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Duloxetine.
CarbamazepineThe metabolism of Duloxetine can be increased when combined with Carbamazepine.
CariprazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Cariprazine.
CaroxazoneCaroxazone may increase the serotonergic activities of Duloxetine.
CarteololCarteolol may increase the orthostatic hypotensive activities of Duloxetine.
CarteololThe metabolism of Carteolol can be decreased when combined with Duloxetine.
CarvedilolCarvedilol may increase the orthostatic hypotensive activities of Duloxetine.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Duloxetine.
CelecoxibThe metabolism of Duloxetine can be decreased when combined with Celecoxib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Duloxetine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Duloxetine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Duloxetine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Duloxetine.
ChlorothiazideChlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Duloxetine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Duloxetine can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Chlorprothixene.
ChlorthalidoneChlorthalidone may increase the orthostatic hypotensive activities of Duloxetine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Duloxetine.
CholecalciferolThe metabolism of Duloxetine can be decreased when combined with Cholecalciferol.
CilazaprilCilazapril may increase the orthostatic hypotensive activities of Duloxetine.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Duloxetine.
CimetidineThe metabolism of Duloxetine can be decreased when combined with Cimetidine.
CinacalcetThe serum concentration of Duloxetine can be increased when it is combined with Cinacalcet.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Duloxetine.
CitalopramThe metabolism of Duloxetine can be decreased when combined with Citalopram.
ClemastineThe metabolism of Duloxetine can be decreased when combined with Clemastine.
ClevidipineClevidipine may increase the orthostatic hypotensive activities of Duloxetine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Duloxetine.
ClobazamThe metabolism of Duloxetine can be decreased when combined with Clobazam.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Duloxetine.
ClonidineClonidine may increase the orthostatic hypotensive activities of Duloxetine.
ClonidineThe metabolism of Clonidine can be decreased when combined with Duloxetine.
ClotrimazoleThe metabolism of Duloxetine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Clozapine.
ClozapineThe metabolism of Duloxetine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Duloxetine can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of Duloxetine can be increased when it is combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Duloxetine.
CyamemazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Cyamemazine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Duloxetine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Duloxetine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Duloxetine.
Cyproterone acetateThe serum concentration of Duloxetine can be decreased when it is combined with Cyproterone acetate.
DapagliflozinDapagliflozin may increase the orthostatic hypotensive activities of Duloxetine.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Duloxetine.
DapiprazoleThe risk or severity of adverse effects can be increased when Duloxetine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Duloxetine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Duloxetine.
DarunavirThe serum concentration of Duloxetine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Duloxetine.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Duloxetine.
DeferasiroxThe serum concentration of Duloxetine can be increased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Duloxetine can be increased when it is combined with Delavirdine.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Duloxetine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Duloxetine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Desvenlafaxine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Duloxetine.
DexmedetomidineDexmedetomidine may increase the orthostatic hypotensive activities of Duloxetine.
DexmedetomidineDuloxetine may decrease the antihypertensive activities of Dexmedetomidine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Duloxetine.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Duloxetine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Duloxetine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Duloxetine.
DiclofenamideDiclofenamide may increase the orthostatic hypotensive activities of Duloxetine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Duloxetine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Duloxetine.
DihydroergotamineDuloxetine may decrease the antihypertensive activities of Dihydroergotamine.
DiltiazemDiltiazem may increase the orthostatic hypotensive activities of Duloxetine.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Duloxetine.
DinutuximabDinutuximab may increase the orthostatic hypotensive activities of Duloxetine.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Duloxetine.
DipivefrinDuloxetine may decrease the antihypertensive activities of Dipivefrin.
DipyridamoleDipyridamole may increase the orthostatic hypotensive activities of Duloxetine.
DolasetronDolasetron may increase the serotonergic activities of Duloxetine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Duloxetine.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Duloxetine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Duloxetine.
DopamineThe metabolism of Dopamine can be decreased when combined with Duloxetine.
DosulepinDuloxetine may increase the serotonergic activities of Dosulepin.
DoxazosinDoxazosin may increase the orthostatic hypotensive activities of Duloxetine.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Duloxetine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Duloxetine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Duloxetine.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Duloxetine.
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Duloxetine.
DroperidolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Droperidol.
DroxidopaDuloxetine may decrease the antihypertensive activities of Droxidopa.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Duloxetine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Duloxetine.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Duloxetine.
EmpagliflozinEmpagliflozin may increase the orthostatic hypotensive activities of Duloxetine.
EnalaprilEnalapril may increase the orthostatic hypotensive activities of Duloxetine.
EncainideThe metabolism of Encainide can be decreased when combined with Duloxetine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Duloxetine.
EphedraDuloxetine may decrease the antihypertensive activities of Ephedra.
EpinastineThe metabolism of Epinastine can be decreased when combined with Duloxetine.
EpinephrineDuloxetine may decrease the antihypertensive activities of Epinephrine.
EplerenoneEplerenone may increase the orthostatic hypotensive activities of Duloxetine.
EprosartanEprosartan may increase the orthostatic hypotensive activities of Duloxetine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Duloxetine.
ErgotamineDuloxetine may decrease the antihypertensive activities of Ergotamine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Duloxetine.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Duloxetine.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Duloxetine.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Duloxetine.
EsmololEsmolol may increase the orthostatic hypotensive activities of Duloxetine.
Etacrynic acidEtacrynic acid may increase the orthostatic hypotensive activities of Duloxetine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Duloxetine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Duloxetine.
EtomidateDuloxetine may decrease the antihypertensive activities of Etomidate.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Duloxetine.
FelodipineFelodipine may increase the orthostatic hypotensive activities of Duloxetine.
FencamfamineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fencamfamine.
FentanylThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Duloxetine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Duloxetine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Duloxetine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Duloxetine.
FluoxetineThe serum concentration of Duloxetine can be increased when it is combined with Fluoxetine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Duloxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fluspirilene.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Duloxetine.
FluvoxamineThe serum concentration of Duloxetine can be increased when it is combined with Fluvoxamine.
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Duloxetine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Duloxetine.
FosinoprilFosinopril may increase the orthostatic hypotensive activities of Duloxetine.
FrovatriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the serotonergic activities of Duloxetine.
FurosemideFurosemide may increase the orthostatic hypotensive activities of Duloxetine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Duloxetine.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Duloxetine.
GranisetronGranisetron may increase the serotonergic activities of Duloxetine.
GranisetronThe metabolism of Granisetron can be decreased when combined with Duloxetine.
GuanabenzDuloxetine may decrease the antihypertensive activities of Guanabenz.
GuanfacineGuanfacine may increase the orthostatic hypotensive activities of Duloxetine.
GuanfacineDuloxetine may decrease the antihypertensive activities of Guanfacine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Duloxetine.
HaloperidolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Haloperidol.
HaloperidolThe metabolism of Duloxetine can be decreased when combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Duloxetine.
HydracarbazineHydracarbazine may increase the serotonergic activities of Duloxetine.
HydralazineHydralazine may increase the orthostatic hypotensive activities of Duloxetine.
HydrochlorothiazideHydrochlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Duloxetine.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Duloxetine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Duloxetine.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Duloxetine.
IloperidoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Iloperidone.
ImatinibThe metabolism of Imatinib can be decreased when combined with Duloxetine.
ImipramineThe metabolism of Duloxetine can be decreased when combined with Imipramine.
IndapamideIndapamide may increase the orthostatic hypotensive activities of Duloxetine.
IndinavirThe metabolism of Duloxetine can be decreased when combined with Indinavir.
Ioflupane I-123Duloxetine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Duloxetine.
IproclozideIproclozide may increase the serotonergic activities of Duloxetine.
IproniazidIproniazid may increase the serotonergic activities of Duloxetine.
IrbesartanIrbesartan may increase the orthostatic hypotensive activities of Duloxetine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Duloxetine is combined with Isocarboxazid.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Duloxetine.
IsoniazidThe metabolism of Duloxetine can be decreased when combined with Isoniazid.
Isosorbide DinitrateIsosorbide Dinitrate may increase the orthostatic hypotensive activities of Duloxetine.
Isosorbide MononitrateIsosorbide Mononitrate may increase the orthostatic hypotensive activities of Duloxetine.
IsoxsuprineIsoxsuprine may increase the orthostatic hypotensive activities of Duloxetine.
IsradipineIsradipine may increase the orthostatic hypotensive activities of Duloxetine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Duloxetine.
KetoconazoleThe metabolism of Duloxetine can be decreased when combined with Ketoconazole.
LabetalolLabetalol may increase the orthostatic hypotensive activities of Duloxetine.
LabetalolThe metabolism of Labetalol can be decreased when combined with Duloxetine.
LevobunololLevobunolol may increase the orthostatic hypotensive activities of Duloxetine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Duloxetine.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Duloxetine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Duloxetine.
LidocaineThe metabolism of Duloxetine can be decreased when combined with Lidocaine.
LinezolidLinezolid may increase the serotonergic activities of Duloxetine.
LinezolidThe risk or severity of adverse effects can be increased when Duloxetine is combined with Linezolid.
LisinoprilLisinopril may increase the orthostatic hypotensive activities of Duloxetine.
LisurideThe metabolism of Lisuride can be decreased when combined with Duloxetine.
LithiumThe risk or severity of adverse effects can be increased when Duloxetine is combined with Lithium.
LofexidineDuloxetine may decrease the antihypertensive activities of Lofexidine.
LomustineThe metabolism of Lomustine can be decreased when combined with Duloxetine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Duloxetine.
LopinavirThe serum concentration of Duloxetine can be increased when it is combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Duloxetine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Duloxetine.
LosartanLosartan may increase the orthostatic hypotensive activities of Duloxetine.
LoxapineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Loxapine.
LumefantrineThe metabolism of Duloxetine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Lurasidone.
MannitolMannitol may increase the orthostatic hypotensive activities of Duloxetine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Duloxetine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Duloxetine.
MebanazineMebanazine may increase the serotonergic activities of Duloxetine.
MecamylamineMecamylamine may increase the orthostatic hypotensive activities of Duloxetine.
MelperoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Melperone.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Duloxetine.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Duloxetine.
MesoridazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Mesoridazine.
MethadoneThe metabolism of Duloxetine can be decreased when combined with Methadone.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Duloxetine.
MethazolamideMethazolamide may increase the orthostatic hypotensive activities of Duloxetine.
MethotrimeprazineThe serum concentration of Duloxetine can be increased when it is combined with Methotrimeprazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Methotrimeprazine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Duloxetine.
MethyclothiazideMethyclothiazide may increase the orthostatic hypotensive activities of Duloxetine.
MethyldopaMethyldopa may increase the orthostatic hypotensive activities of Duloxetine.
Methylene blueDuloxetine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Duloxetine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Duloxetine.
MetipranololMetipranolol may increase the orthostatic hypotensive activities of Duloxetine.
MetoclopramideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Metoclopramide.
MetolazoneMetolazone may increase the orthostatic hypotensive activities of Duloxetine.
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Duloxetine.
MetoprololThe metabolism of Metoprolol can be decreased when combined with Duloxetine.
MexiletineThe serum concentration of Duloxetine can be increased when it is combined with Mexiletine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Duloxetine.
MianserinThe metabolism of Mianserin can be decreased when combined with Duloxetine.
MilnacipranThe risk or severity of adverse effects can be increased when Duloxetine is combined with Milnacipran.
MinaprineThe metabolism of Minaprine can be decreased when combined with Duloxetine.
MinaprineMinaprine may increase the serotonergic activities of Duloxetine.
MinoxidilMinoxidil may increase the orthostatic hypotensive activities of Duloxetine.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Duloxetine.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Duloxetine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Duloxetine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Duloxetine.
MoclobemideMoclobemide may increase the serotonergic activities of Duloxetine.
MoexiprilMoexipril may increase the orthostatic hypotensive activities of Duloxetine.
MolindoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Molindone.
MorphineThe metabolism of Morphine can be decreased when combined with Duloxetine.
NadololNadolol may increase the orthostatic hypotensive activities of Duloxetine.
NaphazolineDuloxetine may decrease the antihypertensive activities of Naphazoline.
NaratriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Naratriptan.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Duloxetine.
NebivololNebivolol may increase the orthostatic hypotensive activities of Duloxetine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Duloxetine.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Duloxetine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Duloxetine.
NesiritideNesiritide may increase the orthostatic hypotensive activities of Duloxetine.
NetupitantThe metabolism of Netupitant can be decreased when combined with Duloxetine.
NevirapineThe metabolism of Duloxetine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Duloxetine.
NicardipineNicardipine may increase the orthostatic hypotensive activities of Duloxetine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Duloxetine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Duloxetine.
NicotineThe metabolism of Nicotine can be decreased when combined with Duloxetine.
NifedipineNifedipine may increase the orthostatic hypotensive activities of Duloxetine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Duloxetine.
NilotinibThe metabolism of Duloxetine can be decreased when combined with Nilotinib.
NimodipineNimodipine may increase the orthostatic hypotensive activities of Duloxetine.
NisoldipineNisoldipine may increase the orthostatic hypotensive activities of Duloxetine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Duloxetine.
NitroglycerinNitroglycerin may increase the orthostatic hypotensive activities of Duloxetine.
NitroprussideNitroprusside may increase the orthostatic hypotensive activities of Duloxetine.
NorepinephrineDuloxetine may decrease the antihypertensive activities of Norepinephrine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Duloxetine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Duloxetine.
OctamoxinOctamoxin may increase the serotonergic activities of Duloxetine.
OlanzapineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Olanzapine.
OlmesartanOlmesartan may increase the orthostatic hypotensive activities of Duloxetine.
OndansetronThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Duloxetine.
OsanetantThe risk or severity of adverse effects can be increased when Duloxetine is combined with Osanetant.
OsimertinibThe serum concentration of Duloxetine can be decreased when it is combined with Osimertinib.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Duloxetine.
OxymetazolineDuloxetine may decrease the antihypertensive activities of Oxymetazoline.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Duloxetine.
PaliperidoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Duloxetine.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Duloxetine.
PanobinostatThe metabolism of Duloxetine can be decreased when combined with Panobinostat.
PapaverinePapaverine may increase the orthostatic hypotensive activities of Duloxetine.
PargylinePargyline may increase the serotonergic activities of Duloxetine.
ParoxetineThe serum concentration of Duloxetine can be increased when it is combined with Paroxetine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Duloxetine.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Duloxetine.
Peginterferon alfa-2bThe serum concentration of Duloxetine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Duloxetine.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Duloxetine.
PergolideDuloxetine may decrease the antihypertensive activities of Pergolide.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Duloxetine.
PerindoprilPerindopril may increase the orthostatic hypotensive activities of Duloxetine.
PerospironeThe risk or severity of adverse effects can be increased when Duloxetine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Perphenazine.
PethidineThe metabolism of Pethidine can be decreased when combined with Duloxetine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Duloxetine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Duloxetine.
PhenelzineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Phenelzine.
PhenelzinePhenelzine may increase the serotonergic activities of Duloxetine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Duloxetine.
PheniprazinePheniprazine may increase the serotonergic activities of Duloxetine.
PhenobarbitalThe metabolism of Duloxetine can be increased when combined with Phenobarbital.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Duloxetine.
PhenylpropanolamineDuloxetine may decrease the antihypertensive activities of Phenylpropanolamine.
PimozideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Pimozide.
PindololPindolol may increase the orthostatic hypotensive activities of Duloxetine.
PindololThe metabolism of Pindolol can be decreased when combined with Duloxetine.
PipamperoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Duloxetine.
PipotiazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Pipotiazine.
PirlindolePirlindole may increase the serotonergic activities of Duloxetine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Duloxetine.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Duloxetine.
PrazosinPrazosin may increase the orthostatic hypotensive activities of Duloxetine.
PrimidoneThe metabolism of Duloxetine can be increased when combined with Primidone.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Duloxetine.
ProcarbazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Prochlorperazine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Duloxetine.
PromazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Promazine.
PromazineThe metabolism of Duloxetine can be decreased when combined with Promazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Duloxetine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Duloxetine.
PropafenoneThe serum concentration of Duloxetine can be increased when it is combined with Propafenone.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Duloxetine.
PropericiazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Propericiazine.
PropofolThe metabolism of Propofol can be decreased when combined with Duloxetine.
PropranololPropranolol may increase the orthostatic hypotensive activities of Duloxetine.
PropranololThe metabolism of Propranolol can be decreased when combined with Duloxetine.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Duloxetine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Duloxetine.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Duloxetine.
QuetiapineQuetiapine may increase the orthostatic hypotensive activities of Duloxetine.
QuetiapineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Quetiapine.
QuinaprilQuinapril may increase the orthostatic hypotensive activities of Duloxetine.
QuinidineThe serum concentration of Duloxetine can be increased when it is combined with Quinidine.
QuinineThe metabolism of Duloxetine can be decreased when combined with Quinine.
RamiprilRamipril may increase the orthostatic hypotensive activities of Duloxetine.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Duloxetine.
RanolazineThe metabolism of Duloxetine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Rasagiline.
RasagilineRasagiline may increase the serotonergic activities of Duloxetine.
RemoxiprideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Remoxipride.
repinotanThe metabolism of repinotan can be decreased when combined with Duloxetine.
ReserpineReserpine may increase the orthostatic hypotensive activities of Duloxetine.
ReserpineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Reserpine.
RifampicinThe metabolism of Duloxetine can be increased when combined with Rifampicin.
RiociguatRiociguat may increase the orthostatic hypotensive activities of Duloxetine.
RisperidoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Risperidone.
RitonavirThe serum concentration of Duloxetine can be increased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Duloxetine.
RizatriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Rizatriptan.
RolapitantThe metabolism of Duloxetine can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Duloxetine can be decreased when combined with Ropinirole.
RopiniroleDuloxetine may decrease the antihypertensive activities of Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Duloxetine.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Duloxetine.
SafrazineSafrazine may increase the serotonergic activities of Duloxetine.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Duloxetine.
SelegilineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Selegiline.
SelegilineSelegiline may increase the serotonergic activities of Duloxetine.
SertindoleThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sertindole.
SertralineThe metabolism of Sertraline can be decreased when combined with Duloxetine.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Duloxetine.
SimeprevirThe metabolism of Duloxetine can be decreased when combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Duloxetine.
SotalolSotalol may increase the orthostatic hypotensive activities of Duloxetine.
SparteineThe metabolism of Sparteine can be decreased when combined with Duloxetine.
SpironolactoneSpironolactone may increase the orthostatic hypotensive activities of Duloxetine.
StiripentolThe serum concentration of Duloxetine can be increased when it is combined with Stiripentol.
SulpirideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sumatriptan.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Duloxetine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Duloxetine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Duloxetine.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Duloxetine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Duloxetine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Duloxetine is combined with Tedizolid Phosphate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Duloxetine.
TelmisartanTelmisartan may increase the orthostatic hypotensive activities of Duloxetine.
TenofovirThe metabolism of Duloxetine can be decreased when combined with Tenofovir.
TerazosinTerazosin may increase the orthostatic hypotensive activities of Duloxetine.
TerbinafineThe serum concentration of Duloxetine can be increased when it is combined with Terbinafine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Duloxetine.
TeriflunomideThe serum concentration of Duloxetine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Duloxetine.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Duloxetine.
TheophyllineThe metabolism of Duloxetine can be decreased when combined with Theophylline.
ThioproperazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Duloxetine.
ThiothixeneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Thiothixene.
TianeptineDuloxetine may increase the serotonergic activities of Tianeptine.
TiclopidineThe metabolism of Duloxetine can be decreased when combined with Ticlopidine.
TimololTimolol may increase the orthostatic hypotensive activities of Duloxetine.
TimololThe metabolism of Timolol can be decreased when combined with Duloxetine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Duloxetine.
TipranavirThe serum concentration of Duloxetine can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Duloxetine.
TizanidineTizanidine may increase the orthostatic hypotensive activities of Duloxetine.
TizanidineDuloxetine may decrease the antihypertensive activities of Tizanidine.
ToloxatoneToloxatone may increase the serotonergic activities of Duloxetine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Duloxetine.
TorasemideTorasemide may increase the orthostatic hypotensive activities of Duloxetine.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Duloxetine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Duloxetine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Duloxetine.
TrandolaprilTrandolapril may increase the orthostatic hypotensive activities of Duloxetine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Duloxetine.
TranylcypromineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Tranylcypromine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Duloxetine.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Duloxetine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Duloxetine.
TriamtereneTriamterene may increase the orthostatic hypotensive activities of Duloxetine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Triflupromazine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Duloxetine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Duloxetine.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Duloxetine.
ValsartanValsartan may increase the orthostatic hypotensive activities of Duloxetine.
VemurafenibThe serum concentration of Duloxetine can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Duloxetine can be decreased when combined with Venlafaxine.
VerapamilVerapamil may increase the orthostatic hypotensive activities of Duloxetine.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Duloxetine.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Duloxetine.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Duloxetine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Duloxetine.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Duloxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Duloxetine.
XylometazolineDuloxetine may decrease the antihypertensive activities of Xylometazoline.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Duloxetine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Duloxetine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ziprasidone.
ZiprasidoneThe metabolism of Duloxetine can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Duloxetine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Duloxetine.
ZotepineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Zuclopenthixol.
Food Interactions
  • Food does not affect maximum levels reached, but delays it (from 6 to 10 hours) and total product exposure appears to be reduced by only 10%.
  • People taking this product who drink large amounts of alcohol are exposed to a higher risk of liver toxicity.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Chen F, Larsen MB, Sanchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005 Mar;15(2):193-8. [PubMed:15695064 ]
  2. Troelsen KB, Nielsen EO, Mirza NR: Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology (Berl). 2005 Oct;181(4):741-50. Epub 2005 Sep 29. [PubMed:16032412 ]
  3. Gould GG, Javors MA, Frazer A: Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain. Biol Psychiatry. 2007 Jan 15;61(2):210-5. Epub 2006 May 2. [PubMed:16650830 ]
  4. Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan 30. [PubMed:17335951 ]
  5. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476 ]
  6. Beique JC, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998 May 15;349(1):129-32. [PubMed:9669506 ]
  7. Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev. 2002 Winter;8(4):361-76. [PubMed:12481192 ]
  8. van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9. [PubMed:2784100 ]
  9. Jost W, Marsalek P: Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. Clin Auton Res. 2004 Aug;14(4):220-7. [PubMed:15316838 ]
  10. Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ: Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008 May;23(3):161-9. doi: 10.1097/YIC.0b013e3282f41d7e. [PubMed:18408530 ]
  11. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S: The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11(12):1475-93. [PubMed:15892657 ]
  12. Khullar V, Cardozo L, Dmochowski R: Mixed incontinence: current evidence and future perspectives. Neurourol Urodyn. 2010 Apr;29(4):618-22. doi: 10.1002/nau.20907. [PubMed:20432324 ]
  13. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470 ]
  14. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML: Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005 Aug;27(8):1126-43. [PubMed:16199241 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Gould GG, Javors MA, Frazer A: Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain. Biol Psychiatry. 2007 Jan 15;61(2):210-5. Epub 2006 May 2. [PubMed:16650830 ]
  3. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476 ]
  4. Beique JC, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998 May 15;349(1):129-32. [PubMed:9669506 ]
  5. Vincent S, Bieck PR, Garland EM, Loghin C, Bymaster FP, Black BK, Gonzales C, Potter WZ, Robertson D: Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004 Jun 29;109(25):3202-7. Epub 2004 Jun 7. [PubMed:15184278 ]
  6. Schou M, Halldin C, Pike VW, Mozley PD, Dobson D, Innis RB, Farde L, Hall H: Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2. Eur Neuropsychopharmacol. 2005 Oct;15(5):517-20. Epub 2005 Apr 7. [PubMed:16139169 ]
  7. Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan 30. [PubMed:17335951 ]
  8. Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev. 2002 Winter;8(4):361-76. [PubMed:12481192 ]
  9. van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9. [PubMed:2784100 ]
  10. Jost W, Marsalek P: Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. Clin Auton Res. 2004 Aug;14(4):220-7. [PubMed:15316838 ]
  11. Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ: Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008 May;23(3):161-9. doi: 10.1097/YIC.0b013e3282f41d7e. [PubMed:18408530 ]
  12. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S: The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11(12):1475-93. [PubMed:15892657 ]
  13. Khullar V, Cardozo L, Dmochowski R: Mixed incontinence: current evidence and future perspectives. Neurourol Urodyn. 2010 Apr;29(4):618-22. doi: 10.1002/nau.20907. [PubMed:20432324 ]
  14. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470 ]
  15. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML: Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005 Aug;27(8):1126-43. [PubMed:16199241 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470 ]
  4. Pereira P, Gianesini J, da Silva Barbosa C, Cassol GF, Von Borowski RG, Kahl VF, Cappelari SE, Picada JN: Neurobehavioral and genotoxic parameters of duloxetine in mice using the inhibitory avoidance task and comet assay as experimental models. Pharmacol Res. 2009 Jan;59(1):57-61. doi: 10.1016/j.phrs.2008.09.014. Epub 2008 Oct 5. [PubMed:18973814 ]
  5. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML: Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005 Aug;27(8):1126-43. [PubMed:16199241 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Knadler MP, Lobo E, Chappell J, Bergstrom R: Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94. doi: 10.2165/11539240-000000000-00000. [PubMed:21366359 ]
  2. Lobo ED, Bergstrom RF, Reddy S, Quinlan T, Chappell J, Hong Q, Ring B, Knadler MP: In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet. 2008;47(3):191-202. [PubMed:18307373 ]
  3. Authors unspecified: Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int. 2006 Oct;15(85):168-72. [PubMed:17121211 ]
  4. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Knadler MP, Lobo E, Chappell J, Bergstrom R: Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94. doi: 10.2165/11539240-000000000-00000. [PubMed:21366359 ]
  2. Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, Guico-Pabia CJ: Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract. 2008 Nov;14(6):368-78. doi: 10.1097/01.pra.0000341891.43501.6b. [PubMed:19057238 ]
  3. Authors unspecified: Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int. 2006 Oct;15(85):168-72. [PubMed:17121211 ]
  4. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 03:41